Cara Therapeutics (NASDAQ:CARA) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.
This is a breakdown of recent ratings and target prices for Cara Therapeutics and Urovant Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cara Therapeutics presently has a consensus target price of $26.93, suggesting a potential upside of 15.33%. Urovant Sciences has a consensus target price of $24.00, suggesting a potential upside of 203.80%. Given Urovant Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Urovant Sciences is more favorable than Cara Therapeutics.
Institutional & Insider Ownership
57.8% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 21.9% of Urovant Sciences shares are owned by institutional investors. 5.8% of Cara Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Cara Therapeutics and Urovant Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Cara Therapeutics and Urovant Sciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cara Therapeutics||$13.47 million||68.91||-$74.01 million||($2.06)||-11.33|
|Urovant Sciences||N/A||N/A||-$111.35 million||($4.43)||-1.78|
Cara Therapeutics has higher revenue and earnings than Urovant Sciences. Cara Therapeutics is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics beats Urovant Sciences on 8 of the 12 factors compared between the two stocks.
About Cara Therapeutics
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.